Expertise in Blood and Bone Marrow Transplant

The Stanford Blood and Marrow Transplant Program combines twenty-five years of treatment expertise with state-of-the-art research and comprehensive support services to assure the best possible outcomes for our patients. Offering treatment for a variety of malignant and non-malignant diseases, including lymphoma, myeloma, leukemia, myelodysplastic syndromes, and selected solid tumors, the Blood and Marrow Transplant Program strives for full reintegration of each patient into normal, everyday life. 

Blood and Bone Marrow Transplant Program
875blakewilburdr-stanford
875 Blake Wilbur Drive
Palo Alto, CA 94304
Phone: 650-723-0822 Getting Here
Conditions Treated
875 Blake Wilbur Drive
Palo Alto, CA 94304
Phone: 650-723-0822 Getting Here

Our Doctors

Care and Treatment at Stanford

Conditions We Treat

The following is a list of diseases treated by the Stanford Blood and Marrow Transplant Program.

Acute myeloid leukemia (AML)

A type of blood cancer in which bone marrow makes too many granulocytes (a type of white blood cell that normally fights infection). The term "acute" means the disease progresses rapidly. 

Acute lymphoblastic leukemia

A cancer of the blood in which too many lymphocytes, a type of white blood cell which normally fights infection, are produced by the bone marrow and by organs of the lymph system. 

Amyloidosis

A disease characterized by an abnormal build up of proteins (called amyloids) in various organs in the body. 

Aplastic anemia

A rare condition that occurs when the body stops producing enough new blood cells, causing fatigue and an increased risk of infections and uncontrolled bleeding. 

Chronic myelogenous leukemia

A chronic form of cancer that starts in the blood-forming cells of the bone marrow and invades the blood and other parts of the body over time.

Chronic lymphocytic leukemia (CLL)

A type of blood cancer in which bone marrow and other lymphatic system organs slowly make too many lymphocytes (a type of white blood cell). The term "chronic" means the disease progresses more slowly.  

Hodgkin's lymphoma

A rare type of lymphatic system cancer which causes some lymphatic cells to abnormally reproduce, eventually creating tumors and making the body less able to fight infection.

Lupus

An autoimmune disease in which the immune system attacks the body's cells and tissue, resulting in widespread, chronic inflammation and tissue damage.

Multiple myeloma

A type of cancer that affects certain white blood cells and collects in the bone marrow and the outer layer of the bone.

Mycosis fungoides

A skin cancer characterized by patches, plaques, and tumors where cancerous cells have invaded the skin. It can also progress to internal organs over time.

Myelodysplastic syndrome

A group of diseases that cause immature blood cells to accumulate in the bone marrow leading to a shortage of mature blood cells.

Microcystic adnexal carcinoma (MAC)

A rare skin cancer. While it’s slow-growing and seldom spreads to other parts of the body, it can grow into nearby fat and muscle and around adjacent nerves without proper treatment.

Non-Hodgkin's lymphoma

A type of cancer of the lymphatic system which can begin in almost any part of the body, causing cells to abnormally reproduce and tumors to eventually grow.

Sarcoma

Cancerous (malignant) tumors of the connective tissues. Sarcoma is classified as bone or soft tissue sarcomas.

Clinical Trials

Stanford's cutting-edge research

The following is some of the research that Blood and Marrow Transplant Program doctors have recently been involved with:

  • Cellular therapeutics—translational research investigating specific cell populations, such as regulatory T-cells, cytokine induced killer (CIK) cells, tumor vaccines, and memory T-cells
  • Graft vs host disease—investigating novel approaches to the prevention and treatment of graft vs host disease
  • Haploidentical hematopoietic (blood forming) cell transplantation
  • Pioneered novel TLI/ATG allogeneic preparative regimen, which reduces rates of graft vs host disease and lowers transplant-related risks in select disease types

Before beginning treatment, ask your doctor about any clinical trials you should consider. Learn more about clinical trials for cancer patients.

Clinical trial eligibility flowcharts

Eligibility flowcharts map clinical trials to specific types of cancers to determine if a participant is eligible for the particular clinical trial. View all blood and marrow transplant eligibility flowcharts at the Stanford Cancer Institute.

For Patients

PREPARE FOR YOUR APPOINTMENT

Review the New Patient Packet for information about:

  • What to expect on the day of your appointment
  • Maps, directions, parking, public transit options, and contact information
  • Other patient resources

The initial evaluation process begins with a referral from your hematologist or oncologist to a Stanford Blood and Marrow Transplantation Program doctor. After this referral, the Stanford Blood and Marrow Transplant Program new patient coordinator will call you with an appointment date and time.

Bring completed forms found in the BMT New Patient Letter.

MEDICAL RELEASE

Please fax the Medical Record Release Form to your new patient coordinator. The medical release form is an authorization form for external facilities to release medical records to Stanford Health Care (formerly Stanford Hospital & Clinics). 

International Patients
Phone: +1 650-723-8561
Email: IMS@stanfordmed.org

For Health Care Professionals

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8:30 a.m. – 5 p.m.

Stanford Health Care (formerly Stanford Hospital & Clinics) provides comprehensive services to refer and track patients, as well as provides the latest information and news for physicians and office staff. For help with all referral needs and questions visit Referring Physicians.

HOW TO REFER

To refer a patient, call our Stanford Blood and Marrow Transplantation Program office at 650-723-0822.

Track your patients' progress and communicate with Stanford providers securely online.

Learn More About PRISM »